Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers
Open Access
- 12 May 2017
- journal article
- research article
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 6
Abstract
Cytokine and growth-factor ligands typically signal through homo- or hetero-dimeric cell surface receptors via Janus Kinase (JAK/TYK), or Receptor Tyrosine Kinase (RTK)-mediated trans-phosphorylation. However, the number of receptor dimer pairings occurring in nature is limited to those driven by natural ligands encoded within our genome. We have engineered synthethic cytokines (synthekines) that drive formation of cytokine receptor dimer pairings that are not formed by endogenous cytokines and that are not found in nature, and which activate distinct signaling programs. We show that a wide range of non-natural cytokine receptor hetero-dimers are competent to elicit a signaling output. We engineered synthekine ligands that assembled IL-2Rβ/IL-4Rα or IL-4Rα/IFNAR2 receptor heterodimers, that do not occur naturally, triggering signaling and functional responses distinct from those activated by the endogenous cytokines IL-2, IL-4, and IFN. Furthermore, hybrid synthekine ligands that dimerized a JAK/STAT cytokine receptor with a receptor tyrosine kinase (RTK) also elicited a signaling response. Synthekines represent a new family of synthetic ligands with pre-defined receptors, but 'orphan' functions, that enable the full combinatorial scope of dimeric signaling receptors encoded within the human genome to be exploited for basic research and drug discovery.Keywords
Funding Information
- Leukemia and Lymphoma Society Career Development Program fellowship
- National Institutes of Health (K01CA175127)
- National Institutes of Health (RO1-AI51321)
- Howard Hughes Medical Institute
This publication has 54 references indexed in Scilit:
- STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptorProceedings of the National Academy of Sciences, 2013
- Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkinesNature Chemical Biology, 2012
- JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated DiseaseImmunity, 2012
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’Nature, 2012
- Interpreting mixed signals: the cell's cytokine conundrumCurrent Opinion in Immunology, 2011
- Structural Linkage between Ligand Discrimination and Receptor Activation by Type I InterferonsCell, 2011
- Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic ContinuumScience, 2011
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Comparable potency of IFNα2 and IFNβ on immediate JAK/STAT activation but differential down-regulation of IFNAR2Biochemical Journal, 2007
- Growth control of hybridoma cells with an artificially induced EpoR-gp130 heterodimerCytotechnology, 2006